Emerging targeted combinations in the management of breast cancer

Rebecca J Lee, Anne C Armstrong, Andrew M WardleyDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UKAbstract: The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cance...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee RJ, Armstrong AC, Wardley AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/81dbad7e4a484275b69c9caab2920b29
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81dbad7e4a484275b69c9caab2920b29
record_format	dspace
spelling	oai:doaj.org-article:81dbad7e4a484275b69c9caab2920b292021-12-02T03:19:52ZEmerging targeted combinations in the management of breast cancer1179-1314https://doaj.org/article/81dbad7e4a484275b69c9caab2920b292013-08-01T00:00:00Zhttp://www.dovepress.com/emerging-targeted-combinations-in-the-management-of-breast-cancer-a14025https://doaj.org/toc/1179-1314Rebecca J Lee, Anne C Armstrong, Andrew M WardleyDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UKAbstract: The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.Keywords: breast cancer, targeted therapy, tyrosine kinase, receptorLee RJArmstrong ACWardley AMDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 61-72 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lee RJ Armstrong AC Wardley AM Emerging targeted combinations in the management of breast cancer
description	Rebecca J Lee, Anne C Armstrong, Andrew M WardleyDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UKAbstract: The number of targeted treatments has risen exponentially over the last few years and is an important concept in the fight against cancer. This review will concentrate on some of the main treatments targeting aberrant pathways which have been tested mainly in the Phase I/II setting. These include human epidermal growth factor receptor 2 inhibitors, drug-antibody conjugates, epidermal growth factor receptor inhibitors, vascular endothelial growth factor inhibitors, reticular activating system, mammalian target of rapamycin and multi-kinase inhibitors. Further knowledge of these pathways and the predictors of response to them will enable personalized medicine to become a reality.Keywords: breast cancer, targeted therapy, tyrosine kinase, receptor
format	article
author	Lee RJ Armstrong AC Wardley AM
author_facet	Lee RJ Armstrong AC Wardley AM
author_sort	Lee RJ
title	Emerging targeted combinations in the management of breast cancer
title_short	Emerging targeted combinations in the management of breast cancer
title_full	Emerging targeted combinations in the management of breast cancer
title_fullStr	Emerging targeted combinations in the management of breast cancer
title_full_unstemmed	Emerging targeted combinations in the management of breast cancer
title_sort	emerging targeted combinations in the management of breast cancer
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/81dbad7e4a484275b69c9caab2920b29
work_keys_str_mv	AT leerj emergingtargetedcombinationsinthemanagementofbreastcancer AT armstrongac emergingtargetedcombinationsinthemanagementofbreastcancer AT wardleyam emergingtargetedcombinationsinthemanagementofbreastcancer
_version_	1718401804298878976

Emerging targeted combinations in the management of breast cancer

Ejemplares similares